Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 20:8:F1000 Faculty Rev-911.
doi: 10.12688/f1000research.17535.1. eCollection 2019.

Medicines in pregnancy

Sarah Je Stock  1 , Jane E Norman  2   3
Affiliations
Review

Medicines in pregnancy

Sarah Je Stock et al. F1000Res. .

Abstract

Medicine use in pregnancy is extremely common, but there are significant knowledge gaps surrounding the safety, dosage and long-term effects of drugs used. Pregnant women have been purposively excluded from clinical trials of the majority of treatments for conditions that may occur concurrently with pregnancy. There is minimal information on the pharmacokinetics of many existing treatments and no systematic capture of long-term outcome data to help inform choices. Treatments commonly used in pregnancy are thus often old and untested, not optimised in dose, and prescribed off-label without adequate safety information. In addition, there has been a staggering lack of investment in drug development for obstetric conditions for decades. This is a major public health concern, and pregnancy complications are the leading cause of mortality in children under five years old globally, and health in pregnancy is a major determinant of women's long-term health and wellbeing. There is an acute need for adequate investment and legislation to boost inclusion of pregnant women in clinical studies, capture high-quality information on medication use in pregnancy in general, and encourage new medicinal product development for obstetric conditions.

Keywords: Child Health; Maternal Health; Medicines; Newborn Health; Pharmacokinetics; Pharmacovigilance; Pregnancy; Public Health.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. Daw JR, Hanley GE, Greyson DL, et al. : Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 2011;20(9):895–902. 10.1002/pds.2184 - DOI - PMC - PubMed
    1. Glover DD, Amonkar M, Rybeck BF, et al. : Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol. 2003;188(4):1039–45. 10.1067/mob.2003.223 - DOI - PubMed
    1. McCormack SA, Best BM: Obstetric Pharmacokinetic Dosing Studies are Urgently Needed. Front Pediatr. 2014;2:9. 10.3389/fped.2014.00009 - DOI - PMC - PubMed
    1. Adam MP, Polifka JE, Friedman JM: Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011;157C(3):175–82. 10.1002/ajmg.c.30313 - DOI - PubMed
    1. Sheffield JS, Siegel D, Mirochnick M, et al. : Designing drug trials: considerations for pregnant women. Clin Infect Dis. 2014;59 Suppl 7:S437–S444. 10.1093/cid/ciu709 - DOI - PMC - PubMed

Publication types